Premium
Immunochemotherapy in human lung cancer using the streptococcal agent OK‐432
Author(s) -
Kimura Ikuro,
Ohnoshi Taisuke,
Yasuhara Shozo,
Sugiyama Motoharu,
Urabe Yasuo,
Fujii Masafumi,
Machida KenIch
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197605)37:5<2201::aid-cncr2820370507>3.0.co;2-q
Subject(s) - medicine , lung cancer , chemotherapy , cancer , lung , stage (stratigraphy) , gastroenterology , oncology , surgery , immunology , paleontology , biology
Streptococcal agent OK‐432 was administered at maintenance levels with conventional inductive chemotherapeutic agents to stage III and IV lung cancer patients. Survival rates were longer in patients treated with OK‐432 than in patients treated without OK‐432. An enhancement of lymphocyte blastogenic activity and a delayed PPD skin reaction were found in patients treated by OK‐432. A low grade fever was present as a side effect of this agent in some patients. The results suggest that OK‐432 may be a useful immunotherapeutic agent in combination with induction chemotherapy in reducing host damage in advanced stages of lung cancer.